Dr Reddys commissions mPEG alcohol manufacturing facility

Published: 17-Mar-2010
Manufacturing

Dedicated facility will operate to c-GMP standards

The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories has successfully commissioned a commercial scale manufacturing facility for pharma grade mPEG alcohols at its Cuernavaca facility in Mexico. It represents a significant investment in a dedicated facility operated to c-GMP standards.

The new facility is capable of producing a wide range of molecular weight mPEGs and has a multitonne annual capacity. The mPEG alcohol manufactured in Mexico will be supplied to Dr. Reddy’s c-GMP facility in Mirfield, UK, where commercial scale activation is carried out.

mPEG alcohols are the key raw materials for Activated mPEG, extensively used for pegylation with biologic drugs and increasingly for peptides and small molecule pharmaceuticals. Dr. Reddy’s has officially branded its extensive range of Activated mPEGs under the name PEGtech.

PEGtech branding has been used to bring together a broad product range comprising a variety of activating groups and molecular weights (5-60 kDa), which are now fully supported by backward integration to the key starting materials. It furthermore highlights the company’s extensive experience in product development and GMP manufacture of the Activated mPEGs.

‘Our investment in the world class mPEG alcohol facility in Mexico underlines our commitment to the growing market for Activated mPEGs,’ said Satish Reddy, managing director and coo, Dr. Reddy’s, ‘By introducing the PEGtech brand, our customers can be assured of the same high quality standards and customer service as they develop their PEGylated biologic drugs or small molecules from the laboratory right through to commercial applications.’
See more

You may also like

Manufacturing

Bracco enters cell therapy manufacturing with microbubble-based cell selection technology

Read more
Bracco Imaging is expanding into cell therapy manufacturing with a bead-free cell selection and activation technology based on its clinically validated microbubble platform

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Overcoming the hurdles of strategic market expansion Ramprasad Kaparaboyena, Regulatory Affairs Manager and QP for Pharmacovigilance at Gaelic Laboratories, discusses how to overcome the challenges of expanding your pharma market into new global regions
  2. Vetter Pharma to build new manufacturing site in Germany as part of €1.5bn global expansion plan The company has submitted a building permit application for a new commercial manufacturing facility in Saarland, Germany, with construction set to begin in Q2 2026 and operations planned for 2031
  3. Drug-loaded pellets: unlocking flexible oral dosage design with modern pelletisation technologies Produced using advanced extrusion–spheronisation technologies such as GEA’s NICA systems, drug-loaded pellets are gaining traction as a flexible and scalable oral solid dosage platform that enhances release control, patient outcomes and manufacturing efficiency
  4. LabIndex - Sourcing solutions powered by a network of world-class suppliers Labtex states: "Using our experience and negotiating power, we can speedily source and procure virtually any type of laboratory equipment or consumables at competitive prices."
  5. New thermal inkjet printer expands AM Labels’ coding portfolio M2 system delivers high resolution variable data printing at production-line speeds

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

You may also like

Manufacturing

Bracco enters cell therapy manufacturing with microbubble-based cell selection technology

Bracco Imaging is expanding into cell therapy manufacturing with a bead-free cell selection and activation technology based on its clinically validated microbubble platform
Manufacturing

New manufacturing line from Adragos granted regulatory approval from Swissmedic

The approval of the new, state-of-the-art facility follows a comprehensive modernisation programme in 2024/2025 that has focussed on ensuring the future-readiness of the plant
Manufacturing

Freudenberg Medical launches new hydrophilic coating LUBRITEQ

The launch comes alongside a comprehensive suite of associated development and manufacturing services designed to remove commercial barriers and enable long-term, trust-based partnerships
Manufacturing

The REACTEX range - cutting-edge components, unmatched precision

Utilising cutting-edge components from leading UK and German manufacturers, the REACTEX range of interchangeable glass reactors offer the following:
Manufacturing

Drug-loaded pellets: unlocking flexible oral dosage design with modern pelletisation technologies

Produced using advanced extrusion–spheronisation technologies such as GEA’s NICA systems, drug-loaded pellets are gaining traction as a flexible and scalable oral solid dosage platform that enhances release control, patient outcomes and manufacturing efficiency
Manufacturing

Vetter Pharma to build new manufacturing site in Germany as part of €1.5bn global expansion plan

The company has submitted a building permit application for a new commercial manufacturing facility in Saarland, Germany, with construction set to begin in Q2 2026 and operations planned for 2031
Manufacturing

Torque of the town - Powerful overhead stirrers from Caframo Lab Solutions

In the UK, Labtex proudly supply a powerful range of overhead stirrers and quality accessories from trusted partners at Caframo Lab Solutions
Subscribe now